LTRN
Lantern Pharma Inc.NASDAQHealthcare$1.62+0.00%ClosedMarket Cap: $18.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
243.20
DCF Value
$398.63
FCF Yield
-86523.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1041.8%
ROA
-155.1%
ROIC
-271.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-17.96B | $-17.11B | $-0.36 | — |
| FY 2025 | $0.00 | NaN% | $-17.98B | $-17.12B | $-1.57 | — |
| Q3 2025 | $0.00 | -Infinity% | $-4.3M | $-4.2M | $-0.39 | — |
| Q2 2025 | $0.00 | NaN% | $-4.7M | $-4.3M | $-0.40 | — |
| Q1 2025 | $0.00 | NaN% | $-4.8M | $-4.5M | $-0.42 | — |
| Q4 2024 | $0.00 | -Infinity% | $-5.9M | $-5.9M | $-0.54 | — |
| FY 2024 | $0.00 | NaN% | $-22.2M | $-20.8M | $-1,930.92 | — |
| Q3 2024 | $0.00 | NaN% | $-5.2M | $-4.5M | $-0.42 | — |
| Q2 2024 | $0.00 | NaN% | $-5.4M | $-5.0M | $-0.46 | — |
| Q1 2024 | $0.00 | NaN% | $-5.7M | $-5.4M | $-0.51 | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.9M | $-4.2M | $-0.39 | — |
| FY 2023 | $0.00 | -Infinity% | $-17.9M | $-16.0M | $-1.47 | — |